drugset / Trial / NCT05789056
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Timeline
- Start
- 2023-03-14
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QRX003 | Unknown | 4 % | Topical |